Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Company announcement – No. 17 / 2022 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 Copenhagen, DK and Boston, MA, May 10 2022 – Zealand Pharma A/S (“Zealand”)...
-
Company announcement – No. 16/ 2022 Zealand Pharma Amends Financing Agreement with Oberland Capital as Part of Company’s Refocused Strategy Amendment reduces the outstanding note principal balance...
-
Company announcement – No. 15 / 2022 Zealand Pharma Hosts Conference Call on May 12 at 4 pm CET (10am ET) to Present First Quarter Results for 2022 Copenhagen, DK and Boston, MA, U.S. May 5,...
-
Company announcement – No. 15 / 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities Copenhagen, DK and Boston, MA, April 22, 2022 – Zealand Pharma...
-
Company announcement – No. 14 / 2022 Zealand Pharma launches long-term incentive program for Zealand’s Board of Directors for 2022 Copenhagen, DK and Boston, MA, US., April 20, 2022 – Zealand Pharma...
-
Company announcement – No. 13 / 2022 CORRECTION: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022 Copenhagen, DK and Boston, MA, April 7, 2022 – Zealand Pharma A/S...
-
Company announcement – No. 13 / 2022 Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022 Copenhagen, DK and Boston, MA, April 7, 2022 – Zealand Pharma A/S...
-
Company announcement – No. 12 / 2022 Zealand Pharma's Annual General Meeting 2022 Copenhagen, April 6, 2022 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held its...
-
Company announcement – No. 11 / 2022 Zealand Pharma to Participate in 21st Annual Needham Virtual Healthcare Conference Copenhagen, DK and Boston, MA, U.S. April 4, 2022 – Zealand Pharma A/S...
-
Company announcement – No. 10 / 2022 Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines Operations ...